FDA: new safety information for recombinant erythropoietins

By  

Inpharma, Vol. 1, Iss. 1579, 2007-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Biological and Biochemical Assays to Ensure the Quality and Safety of Plasma-Derived Products: Factor VIII Concentrates

By  

Current Pharmaceutical Analysis, Vol. 3, Iss. 2, 2007-05 ,pp. : 83-94

Bentham Science Publishers

Access to resources Recommend Favorite

The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients

By Wilson Stephen J   Bellamy Mark C   Giannoudis Peter V  

Expert Opinion on Drug Safety, Vol. 4, Iss. 3, 2005-05 ,pp. : 557-570

Informa Healthcare

Access to resources Recommend Favorite

On the safety of a new generation of DSM Aspergillus niger enzyme production strains

By van Dijck P.W.M.   Selten G.C.M.   Hempenius R.A.  

Regulatory Toxicology and Pharmacology, Vol. 38, Iss. 1, 2003-08 ,pp. : 27-35

Elsevier

Access to resources Recommend Favorite

New Insights into the Coagulation System and Implications for New Therapeutic Options with Recombinant Factor VIIa

By  

Current Medicinal Chemistry, Vol. 10, Iss. 10, 2003-05 ,pp. : 797-811

Bentham Science Publishers

Access to resources Recommend Favorite